N-[1-[3-(difluoromethylsulfonylamino)phenyl]cyclopropyl]-4-(6-ethoxypyrazin-2-yl)-2-fluorobenzamide
C23H21F3N4O4S — CID 163271277
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[1-[3-(difluoromethylsulfonylamino)phenyl]cyclopropyl]-4-(6-ethoxypyrazin-2-yl)-2-fluorobenzamide
N-[1-[3-(difluoromethylsulfonylamino)phenyl]cyclopropyl]-4-(6-ethoxypyrazin-2-yl)-2-fluorobenzamide (PubChem CID 163271277) has the molecular formula C23H21F3N4O4S and a molecular weight of 506.51 g/mol. Its IUPAC name is N-[1-[3-(difluoromethylsulfonylamino)phenyl]cyclopropyl]-4-(6-ethoxypyrazin-2-yl)-2-fluorobenzamide.
Molecular Properties
| Compound Name | N-[1-[3-(difluoromethylsulfonylamino)phenyl]cyclopropyl]-4-(6-ethoxypyrazin-2-yl)-2-fluorobenzamide |
|---|---|
| PubChem CID | 163271277 |
| Molecular Formula | C23H21F3N4O4S |
| Molecular Weight | 506.51 g/mol |
| Exact Mass | 506.12 |
| IUPAC Name | N-[1-[3-(difluoromethylsulfonylamino)phenyl]cyclopropyl]-4-(6-ethoxypyrazin-2-yl)-2-fluorobenzamide |
| SMILES | CCOc1cncc(-c2ccc(C(=O)NC3(c4cccc(NS(=O)(=O)C(F)F)c4)CC3)c(F)c2)n1 |
| InChI | InChI=1S/C23H21F3N4O4S/c1-2-34-20-13-27-12-19(28-20)14-6-7-17(18(24)10-14)21(31)29-23(8-9-23)15-4-3-5-16(11-15)30-35(32,33)22(25)26/h3-7,10-13,22,30H,2,8-9H2,1H3,(H,29,31) |
| InChIKey | RSTBCBXWRACCIE-UHFFFAOYSA-N |
| XLogP | 4.06 |
| TPSA | 110.28 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 9 |
| Heavy Atoms | 35 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 506.51 |
| LogP ≤ 5 | 4.06 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 163271277 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.